SELLAS Life Sciences Group, Inc.
HealthcareNASDAQ:SLS · NASDAQ Capital Market
+$0.08 today
Vol 4.06M · Avg 7.80M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $107.2M |
| Other Current | $4.0M |
| Total Current Assets | $111.2M |
| PP&E (Net) | $839.0K |
| Goodwill | $1.9M |
| Other Non-current | $255.0K |
| Total Non-current Assets | $3.0M |
| Total Assets | $114.2M |
Analysis
Selected assets total $114.2M for Latest. The largest visible component is Cash & Equivalents at $107.2M, about 93.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.9M +417.7% | $13.9M +448.9% | $2.5M -85.2% | $17.1M -20.2% | $21.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3.3M +3218.0% | $100.0K +0.0% | $100.0K -69.7% | $330.0K +1122.2% | $27.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $75.2M +360.7% | $16.3M +414.7% | $3.2M -82.1% | $17.8M -22.9% | $23.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $963.0K +4.1% | $925.0K +7.8% | $858.0K -1.8% | $874.0K +20.9% | $723.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $1.9M +0.0% | $1.9M +0.0% | $1.9M +0.0% | $1.9M +0.0% | $1.9M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 +100.0% | -$184.0K | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 -100.0% | $184.0K +21.1% | $152.0K | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $257.0K -44.8% | $466.0K +69.5% | $275.0K -31.1% | $399.0K -32.8% | $594.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $3.1M -5.2% | $3.3M +8.5% | $3.0M -4.4% | $3.2M -5.8% | $3.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $78.3M +303.2% | $19.4M +212.5% | $6.2M -70.3% | $20.9M -20.8% | $26.4M | $13.3B | $11.9B | $10.6B |
| Account Payables | $2.9M -15.8% | $3.5M -37.9% | $5.6M +68.0% | $3.4M +56.6% | $2.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $544.0K | $0 | $0 | $0 -100.0% | $198.0K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $3.5M +93.8% | $1.8M +18.5% | $1.5M -72.1% | $5.5M +233.1% | $1.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $7.0M -26.2% | $9.5M -30.8% | $13.7M -11.5% | $15.5M +211.4% | $5.0M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 -100.0% | $184.0K +21.1% | $152.0K | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 +100.0% | -$184.0K | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 -100.0% | $4.0K -98.8% | $336.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $457.0K +0.0% | $457.0K -0.7% | $460.0K -20.3% | $577.0K -47.4% | $1.1M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.5M -25.0% | $10.0M -29.8% | $14.2M -11.8% | $16.1M +164.7% | $6.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $15.0K +114.3% | $7.0K +133.3% | $3.0K +50.0% | $2.0K +0.0% | $2.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$275.0M -10.8% | -$248.1M -14.2% | -$217.2M -20.8% | -$179.9M -29.8% | -$138.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $70.9M +648.8% | $9.5M +218.7% | -$8.0M -264.4% | $4.9M -76.2% | $20.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $1.0M +0.0% | $1.0M +10.5% | $906.0K -4.1% | $945.0K +17.0% | $808.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$70.9M -450.2% | -$12.9M -693.4% | -$1.6M +90.0% | -$16.2M +21.6% | -$20.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SLS have?
SELLAS Life Sciences Group, Inc. (SLS) reported $71.89M in cash and equivalents in fiscal 2025.
How much debt does SLS carry?
SELLAS Life Sciences Group, Inc. (SLS) reported $1.00M of total debt, with net debt of -$70,892,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.